Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Gsk-1059615. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 5/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 3/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 3/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 5/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 1.00 |
| ▸ | CLK1 | P49759 | 3/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-1059615 SCHEMBL1805561 | 1.00 | PIK3CA (1.00) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| Gsk-1059615 SCHEMBL1805557 | 1.00 | PIK3CA (1.00) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| Gsk-1059615 SCHEMBL29351551 | 1.00 | PIK3CA (1.00) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| Gsk-1059615 SCHEMBL29381321 | 1.00 | PIK3CA (1.00) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| SCHEMBL13591345 | 0.88 | PIM1 (0.78) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| SCHEMBL729541 | 0.88 | PIK3CA (0.77) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| SCHEMBL729542 | 0.88 | PIK3CA (0.77) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| SCHEMBL4396728 | 0.87 | PIK3CA (0.77) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| SCHEMBL4396725 | 0.87 | PIK3CA (0.77) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG | |
| SCHEMBL13739026 | 0.86 | PIK3CA (0.76) | PIK3CAPIM1PIK3CDCSNK2A2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11304939-B2 | Methods for treating oral cancers | CHANG GUNG UNIVERSITY (TW) | 2022-04-19 | — | — | US | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| US-20210353605-A1 | METHODS FOR TREATING ORAL CANCERS | CHANG GUNG UNIVERSITY (TW) | 2021-11-18 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | claimed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | claimed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | claimed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4320150-A1 | USES OF ANTI-TGF BETA ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R1 | PIK3CA 10/4885PIK3CD 5/4885PIK3CG 8/4885 |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | PIK3R5, PIK3C2A, PIK3C2B | PIK3CA 9/4885PIK3CD 6/4885PIK3CG 5/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | PIK3CA 2400/4885PIK3CD 3852/4885PIK3CG 4202/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | PIK3CA 2451/4885PIK3CD 2773/4885PIK3CG 2526/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PIK3CA 2528/4885PIK3CD 2475/4885PIK3CG 2294/4885 |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R3 | PIK3CA 10/4885PIK3CD 6/4885PIK3CG 9/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PIK3CA 2451/4885PIK3CD 2773/4885PIK3CG 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.